VIDEO and FREE TRIAL
Qlucore Omics Explorer video
Qlucore Omics Explorer free trial
Clinical diagnostics
Bringing precision medicine and molecular diagnostics to the clinic
Precision medicine is transforming diagnostics from traditional phenotypic information obtained from cellular analysis to advanced molecular diagnostics from transcriptomics and genetic analysis. By leveraging large, complex datasets rich in disease-relevant information, we can significantly enhance disease identification, classification, and treatment strategies.
Historically, the rapid generation of extensive datasets from next-generation sequencing (NGS) has outpaced the development of efficient tools for analysis. Qlucore Diagnostics bridges this gap. Using disease specific machine-learning classifiers, genetic subtype information can be uncovered. The result is presented in clear and visual reports. This enables clinical labs to perform molecular diagnostics without specialized training.
In addition to our CE-marked Qlucore Diagnostics platform for BCP-ALL, we have research use only solutions for lung and bladder cancer available. We are also actively partnering to advance diagnostic tools for other diseases.
Cancer diagnostics: in transformation
Cancer diagnostics are rapidly evolving towards precision-based treatments for various cancer types. This evolution is driven by the decreasing cost of genetic screening as well as breakthroughs in research. Qlucore plays a crucial role in this transformation, with our innovative software solutions for precision diagnostics. The first CE-marked product is for Acute Lymphoblastic Leukemia (BCP-ALL).
Unique functionality for easy deployment
Qlucore solutions include machine learning based subtype classification and gene fusion analysis, combined with easy-to-understand reporting and visualization for clear communication.
- AI-powered, disease-specific machine learning classifier models based on gene expression.
- Plug-in software architecture for scalability to multiple disease areas.
- Tier-based gene fusion reporting.
- Patient-friendly visualizations in an easy-to-use and cost-effective software solution.
- Based on RNA sequencing data and standard NGS workflows.
Falling costs
Driven by the falling costs of Next Generation Sequencing (NGS) techniques, precision diagnostics and personalized treatments are improving at a fast pace.
RNA-seq based cancer diagnostics
International research has shown that transcriptional profiling of cancer significantly enhances clinical diagnosis, therapy selection and prediction of disease/treatment outcome. The detection and analysis of gene fusions and expression-based classification are rapidly transitioning from research to clinical practice. Gene fusions, key genetic alterations detectable by RNA-sequencing, are crucial diagnostic markers for leukemia (ALL and AML) according to current guidelines.
Transcriptomics - paving the way for improved diagnostics and precision medicine
The rapid advancement and cost reductions of NGS techniques is shifting clinical diagnostics from small gene panels to more comprehensive approaches. As the number of drug candidates targeting gene fusions increases, so does the need for broad coverage to improve diagnosis and treatment selection.
Whole transcriptome RNA-seq data provides unbiased gene fusion detection and a comprehensive gene expression signature of tumors, essential for accurate patient subtype classification and diagnosis.
Stay Ahead with Qlucore’s Clinical Diagnostics Solutions
The latest developments in precision medicine demand clinical labs to stay current and implement new techniques. With Qlucore solutions, you can begin this transition in your lab. Over 300 genes are frequently involved in gene fusions across various cancers, making our tools indispensable for modern diagnostics.